Brief: Mirum Pharmaceuticals Announces Primary Endpoint Met In Phase 2B Portion Of The Azure-1 Study
27/04/2026 13:45
April 27 (Reuters) - Mirum Pharmaceuticals Inc MIRM.O: MIRUM PHARMACEUTICALS ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2B PORTION OF THE AZURE-1 STUDY OF BRELOVITUG IN CHRONIC HEPATITIS DELTA VIRUS MIRUM PHARMACEUTICALS INC - ANNOUNCES PRIMARY ENDPOINT MET IN PHASE 2B AZURE-1 STUDY OF BRELOVITUG MIRUM PHARMACEUTICALS INC - PRIMARY ENDPOINT ACHIEVED IN BOTH DOSE ARMS AT WEEK 24 MIRUM PHARMACEUTICALS INC: FAVORABLE SAFETY AND TOLERABILITY PROFILES OBSERVED MIRUM PHARMACEUTICALS INC - TOPLINE PHASE 3 DATA FROM AZURE-1 AND AZURE-4 EXPECTED IN H2 2026 Source text: ID:nBw9Zyza Further company coverage: MIRM.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX